Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a member of a category of neurodegenerative diseases characterized by the conformational change of a normal protein into a pathological conformer with a high β-sheet content that renders it resistant to degradation and neurotoxic. In the case of AD the normal soluble amyloid β (sAβ) peptide is converted into oligomeric/fibrillar Aβ. The oligomeric forms of Aβ are thought to be the most toxic, while fibrillar Aβ becomes deposited as amyloid plaques and congophilic angiopathy, which both serve as neuropathological markers of the disease. In addition, the accumulation of abnormally phosphorylated tau as soluble toxic oligomers and as neurofibrillary tangles is an essential part of the pathology. Many therapeutic interventions are under investigation to prevent and treat AD. The testing of these diverse approaches to ameliorate AD pathology has been made possible by the existence of numerous transgenic mouse models which each mirror different aspects of AD pathology. Perhaps the most exciting of these approaches is immunomodulation. Vaccination is currently being tried for a range of age associated CNS disorders with great success being reported in many transgenic mouse models. However, there is a discrepancy between these results and current human clinical trials which highlights the limitations of current models and also uncertainties in our understanding of the underlying pathogenesis of AD. No current AD Tg mouse model exactly reflects all aspects of the human disease. Since the underlying etiology of sporadic AD is unknown, the process of creating better Tg models is in constant evolution. This is an essential goal since it will be necessary to develop therapeutic approaches which will be highly effective in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 2×
“Several behavioral tests have shown age-dependent impairment with cognitive tasks (Arendash et al. 2001; Hsiao et al. 1996; Lesne et al. 2006; Morgan et al. 2000; Sigurdsson et al. 2004; Tagliavini et al. 1991).”
BackgroundRetractedImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 4×
“AD Tg model mice treated this way had a significantly reduced Aβ level and demonstrated cognitive benefit (Bard et al. 2000; DeMattos et al. 2001; Dodart et al. 2002; Levites et al. 2006; McLaurin et al. 2002).”
BackgroundInfluentialReducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 2×
“…it has been shown that reducing the level of endogenous mouse tau can prevent behavioral deficits in APP Tg mice without affecting Ab levels (Roberson et al. 2007) and that exogenous Ab extracted from AD Tg mice can accelerate plaque deposi- tion in predisposed young Tg mice (Eisele et al.…”
BackgroundTwenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661 · cited 5×
“Many studies have shown that the inheritance of the apoE4 allele is the single most important genetic risk factor for late-onset AD identified so far (Kim et al. 2009; Wisniewski and Sadowski 2008).”
BackgroundInfluentialEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“Some of these mice display NFTs, neuronal death and behavioral deficits (Egashira et al. 2005; Gotz et al. 2000, 2001a; Gotz and Ittner 2008; Ishihara et al. 2001; Lee et al. 2005; Lewis et al. 2001; Murakami et al. 2006; Tanemura et al. 2001; Yoshiyama et al. 2007).”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 2×
“Some of these mice display NFTs, neuronal death and behavioral deficits (Egashira et al. 2005; Gotz et al. 2000, 2001a; Gotz and Ittner 2008; Ishihara et al. 2001; Lee et al. 2005; Lewis et al. 2001; Murakami et al. 2006; Tanemura et al. 2001; Yoshiyama et al. 2007).”
BackgroundTwo amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., Prada, C.-M., Kim, G., Seekins, S., Yager, D., et al. (1996) · Neuron · doi:10.1016/s0896-6273(00)80230-5 · Cited by 1,478
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 3×
“…404 Subcutaneously with alum adjuvant Asuni et al. (2007) Human tau PS1 Tau peptide 379–408, phosphorylated at Ser 396, Ser 404 Subcutaneously with alum adjuvant Boutajangout et al. (2008) was no evidence of improved survival or an improvement in the time to severe dementia (Holmes et al. 2008).”
BackgroundMethodNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 2×
“…features were the persis- tence of amyloid in cerebral vessels, as well as unaltered tau immunoreactive NFTs and neuropil threads in regions of cerebral cortex where plaque clearing had apparently occurred, compared to regions without clearing (Masliah et al. 2005a; Nicoll et al. 2005, 2006).”
BackgroundResultReiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 1×
“…significance of apoE expression has been well documented by autopsy studies and by neuro- imaging, showing that apoE4 expressing individuals have a higher amyloid burden and glucose utilization abnormali- ties even in presymptomatic stages of AD (Kok et al. 2009; Reiman et al. 1996, 2004, 2009).”
BackgroundClinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 2×
“Similar effects on Ab load and behavior have been demonstrated in AD Tg mice by peripheral injections of anti-Ab monoclonal antibodies indicating that the therapeutic effect of the vaccine is based primarily on eliciting a humoral response (Bard et al. 2000; DeMattos et al. 2001).”
BackgroundBillings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294
Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-wood, K., Lee, M., Seubert, P., Davis, A., et al. (1997) · Nature Medicine · doi:10.1038/nm0197-67 · Cited by 1,271 · cited 1×
“PS is part of the c-secretase complex and FAD linked mutations are associated with an increase in Ab42 production (Borchelt et al. 1996; Citron et al. 1997; Wolfe 2009).”
BackgroundCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 2×
“However, evidence proving that Ab is central in the common late-onset sporadic form of AD is more limited: (1) a correlation has been shown between biochemically extracted Ab peptides species from sporadic AD brains with cognitive decline (Naslund et al. 2000).”
BackgroundPropagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · cited 2×
“…shown that extracellular tau aggregates can be internalized and promote the fibrillization of intracellular full length tau in a tissue culture model (Frost et al. 2009) and that injection of fibrillar tau brain extract into the brains of transgenic wild-type expressing mice can induce the…”
BackgroundGoedert, M., Wischik, C. M., Crowther, R. A., Walker, J. E., & Klug, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4051 · Cited by 1,134 · cited 1×
“In the CNS, human tau is expressed in six isoforms arising from alternative mRNA splicing from a single gene on chromosome 17q21, containing 16 exons (Goedert et al. 1988, 1989).”
BackgroundKawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 2×
“The brain amyloid β levels start increasing at 6 months and Aβ parenchymal deposits start developing between 9 and 12 months (Hsiao et al. 1996; Kawarabayashi et al. 2001).”
BackgroundBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986 · cited 3×
“Crossing PS1 mutation mice with APP Tg models dramatically increases amyloid deposition, thought to be due to increased Ab42 production (Borchelt et al. 1997; Duff et al. 1996; Holcomb et al. 1998; Radde et al. 2006).”
BackgroundResultAmyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease
Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980 · cited 4×
“In this model, the tau pathology is observed first in the hippocampus and then progresses to the cortex (Oddo et al. 2003a).”
BackgroundMethodInfluentialFunctional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977 · cited 1×
“…significance of apoE expression has been well documented by autopsy studies and by neuro- imaging, showing that apoE4 expressing individuals have a higher amyloid burden and glucose utilization abnormali- ties even in presymptomatic stages of AD (Kok et al. 2009; Reiman et al. 1996, 2004, 2009).”
BackgroundExogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 2×
“(3) Ab extracted from sporadic AD patients has been shown to induce amyloid deposits when injected into transgenic mice (Meyer-Luehmann et al. 2006).”
BackgroundChishti, M. A., Yang, D.-S., Janus, C., Phinney, A. L., Horne, P., Pearson, J., Strome, R., Zuker, N., Loukides, J., French, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100710200 · Cited by 955 · cited 4×
“This study showed that despite evidence of very significant amyloid plaque removal in six out of the eight autopsy subjects, which correlated with the anti-Ab titer, in the overall group there APP(K670N, M671L, V717F) Tg CRND8 Ab1-40 and Ab1-42 Specific antibodies Passive Levites et al. (2006) APP(K670N, M671L), Tg 25…”
MethodInfluentialEl Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., & Luster, A. D. (2007) · Nature Medicine · doi:10.1038/nm1555 · Cited by 915
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · cited 2×
“AD Tg model mice treated this way had a significantly reduced Aβ level and demonstrated cognitive benefit (Bard et al. 2000; DeMattos et al. 2001; Dodart et al. 2002; Levites et al. 2006; McLaurin et al. 2002).”
BackgroundLack of apolipoprotein E dramatically reduces amyloid β-peptide deposition
Bales, K. R., Verina, T., Dodel, R. C., Du, Y., Altstiel, L., Bender, M., Hyslop, P., Johnstone, E. M., Little, S. P., Cummins, D. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-263 · Cited by 830
Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid
Wisniewski, T., & Frangione, B. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90444-c · Cited by 802 · cited 2×
“2007; Wisniewski and Sadowski 2008); however, one suggested role for apoE has been as a ‘‘pathological chaperone’’ that can induce a b-sheet conformation in Ab (Sadowski et al. 2006; Wisniewski et al. 1993, 1994; Wisniewski and Frangione 1992).”
BackgroundReiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785 · cited 1×
“…significance of apoE expression has been well documented by autopsy studies and by neuro- imaging, showing that apoE4 expressing individuals have a higher amyloid burden and glucose utilization abnormali- ties even in presymptomatic stages of AD (Kok et al. 2009; Reiman et al. 1996, 2004, 2009).”
BackgroundStructural Classification of Toxic Amyloid Oligomers
Glabe, C. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800016200 · Cited by 783 · cited 2×
“Abundant evidence both in vivo and in vitro suggests that the most toxic species of Ab are oligomers or Ab derived diffusible ligands (ADDLs) (Glabe 2008; Klybin et al. 2008) with a similar line of evidence suggesting that tau oligomers are the most toxic form of phosphorylated tau (Kayed and…”
BackgroundPicomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus
Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., & Arancio, O. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2692-08.2008 · Cited by 740 · cited 3×
“…important factor to consider is that emerging evidence suggests that monomeric Ab peptides have normal physiological functions in the brain such as neuroprotection and mod- ulating LTP (Giuffrida et al. 2009; Puzzo et al. 2008), with phosphorylated tau also having a normal role (Noble et al. 2009).”
BackgroundHyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Alzheimer disease and cerebrovascular pathology: an update
Jellinger, K. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200068 · Cited by 680 · cited 16×
“Furthermore CAA is present in about 33% of cognitively normal elderly, control populations (Zhang-Nunes et al. 2006).”
BackgroundInfluentialIncidence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study
Vermeer, S. E., den Heijer, T., Koudstaal, P. J., Oudkerk, M., Hofman, A., & Breteler, M. M. B. (2003) · Stroke · doi:10.1161/01.str.0000052631.98405.15 · Cited by 680 · cited 2×
“Strategically placed microhemorrhages in patients have been shown to correlate with cognitive deficits (Kramer et al. 2002; Vermeer et al. 2003).”
BackgroundAnimal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · cited 2×
“Some of these mice display NFTs, neuronal death and behavioral deficits (Egashira et al. 2005; Gotz et al. 2000, 2001a; Gotz and Ittner 2008; Ishihara et al. 2001; Lee et al. 2005; Lewis et al. 2001; Murakami et al. 2006; Tanemura et al. 2001; Yoshiyama et al. 2007).”
BackgroundIRIZARRY, M. C., MCNAMARA, M., FEDORCHAK, K., HSIAO, K., & HYMAN, B. T. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199709000-00002 · Cited by 649
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 3×
“The Ab1-42 expressing mice developed extensive cored plaques, dif- fuse plaques and CAA (at older ages), in contrast to the Ab1-40 mice which did not develop amyloid deposits at any age (McGowan et al. 2005).”
BackgroundMechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Lemere, C. A., Blusztajn, J. K., Yamaguchi, H., Wisniewski, T., Saido, T. C., & Selkoe, D. J. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0003 · Cited by 584 · cited 2×
“(2) Down’s syndrome, where there is an extra copy of the APP gene due to trisomy 21, is associated with AD related pathology at a very early age (Lemere et al. 1996).”
BackgroundSelf-citationFibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches
Tsai, J., Grutzendler, J., Duff, K., & Gan, W.-B. (2004) · Nature Neuroscience · doi:10.1038/nn1335 · Cited by 561 · cited 2×
“…have shown neurite displacement, dendritic spine loss, thinning of dendrites and dendritic breakage adjacent to amyloid pla- ques suggesting that dense cored amyloid plaques do contribute at least partially to the cognitive abnormalities found in these mice (Spires et al. 2005; Tsai et al. 2004).”
BackgroundSpires, T. L., Meyer-Luehmann, M., Stern, E. A., McLean, P. J., Skoch, J., Nguyen, P. T., Bacskai, B. J., & Hyman, B. T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1879-05.2005 · Cited by 550 · cited 3×
“…have shown neurite displacement, dendritic spine loss, thinning of dendrites and dendritic breakage adjacent to amyloid pla- ques suggesting that dense cored amyloid plaques do contribute at least partially to the cognitive abnormalities found in these mice (Spires et al. 2005; Tsai et al. 2004).”
BackgroundTau protein binds to microtubules through a flexible array of distributed weak sites.
Butner, K. A., & Kirschner, M. W. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.3.717 · Cited by 550
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · cited 2×
“A number of investigators have suggested alternative theories, whereby accumulation of Ab and tau hyperphosphorylation are dual pathways both downstream from a common upstream pathogenic deficit (which remains to be identified) (Castellani et al. 2008; Shioi et al. 2007; Small and Duff 2008).”
BackgroundEffects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Grabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W., & Greenberg, S. M. (2001) · Annals of Neurology · doi:10.1002/ana.1009 · Cited by 523
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms
Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511 · cited 1×
“…did not develop NFTs, with the exception of two models: One expressing ON3R wild-type tau with a few NFTs in aged animals (Ishihara et al. 2001) and another with abundant NFTs that expresses all six human tau iso- forms on a knockout background for murine tau (Andorfer et al. 2003, 2005).”
BackgroundCerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · cited 5×
“Recently, it has been shown that active immunization of Tg mice P301L with a phospho-tau peptide (containing the phosphorylated PHF-1 epitopes Ser 396, Ser 404) for 2– 5 months could prevent tau related pathology (Asuni et al. 2007).”
BackgroundMethodInfluentialSelf-citationNeuron loss in APP transgenic mice
Calhoun, M. E., Wiederhold, K.-H., Abramowski, D., Phinney, A. L., Probst, A., Sturchler-Pierrat, C., Staufenbiel, M., Sommer, B., & Jucker, M. (1998) · Nature · doi:10.1038/27351 · Cited by 502 · cited 2×
“Two Tg lines with some neuronal loss are the APP23 mice (Calhoun et al. 1998; SturchlerPierrat et al. 1997) and a line with both the Swedish and London FAD APP mutations, along with two PS1 mutations (M233T/L235P) (Casas et al.”
BackgroundIrizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., & Hyman, B. T. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-18-07053.1997 · Cited by 497 · cited 3×
“One of the limitations of the existing Tg amyloid models is the relative lack of neuronal loss, contrasting to what is found in AD (Frautschy et al. 1998; Irizarry et al. 1997b; Takeuchi et al. 2000).”
MethodResultTau filament formation in transgenic mice expressing P301L tau
Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495 · cited 2×
“Some of these mice display NFTs, neuronal death and behavioral deficits (Egashira et al. 2005; Gotz et al. 2000, 2001a; Gotz and Ittner 2008; Ishihara et al. 2001; Lee et al. 2005; Lewis et al. 2001; Murakami et al. 2006; Tanemura et al. 2001; Yoshiyama et al. 2007).”
BackgroundRole of toll-like receptor signalling in A uptake and clearance
Tahara, K., Kim, H.-D., Jin, J.-J., Maxwell, J. A., Li, L., & Fukuchi, K.-I. (2006) · Brain · doi:10.1093/brain/awl249 · Cited by 493 · cited 2×
“Stimulation of peripheral macrophages to enter the CNS and phagocytose amyloid has been achieved by stimulation of the Toll-like receptor nine using unmethylated cytosine-guanosine oligonucleotides (CpG) (Scholtzova et al. 2009; Tahara et al. 2006), via blockade of the CD40/CD40L interaction (Obregon et al.”
MethodThe role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
A Hundred Years of Alzheimer's Disease Research
Hardy, J. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.016 · Cited by 467
A stop-codon mutation in the BRI gene associated with familial British dementia
Vidal, R., Frangione, B., Rostagno, A., Mead, S., Révész, T., Plant, G., & Ghiso, J. (1999) · Nature · doi:10.1038/21637 · Cited by 466
Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology
Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C. A., Tan, J., Duman, R. S., & Flavell, R. A. (2008) · Nature Medicine · doi:10.1038/nm1781 · Cited by 422 · cited 2×
“2008) and by blockade of TGFb-Smad2/3 innate signaling pathway (Town et al. 2008).”
BackgroundMethodβ-Amyloid Monomers Are Neuroprotective
Giuffrida, M. L., Caraci, F., Pignataro, B., Cataldo, S., De Bona, P., Bruno, V., Molinaro, G., Pappalardo, G., Messina, A., Palmigiano, A., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1736-09.2009 · Cited by 421 · cited 3×
“…important factor to consider is that emerging evidence suggests that monomeric Ab peptides have normal physiological functions in the brain such as neuroprotection and mod- ulating LTP (Giuffrida et al. 2009; Puzzo et al. 2008), with phosphorylated tau also having a normal role (Noble et al. 2009).”
BackgroundCasas, C., Sergeant, N., Itier, J.-M., Blanchard, V., Wirths, O., van der Kolk, N., Vingtdeux, V., van de Steeg, E., Ret, G., Canton, T., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63388-3 · Cited by 400
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379 · cited 2×
“…in transgenic mouse models of both mutant APP and tau over-expression (with both amyloid and tau related pathology) prevention of Ab pathology leads to both amelioration of cognitive deficits and tau related pathology (Blurton-Jones and LaFerla 2006; McKee et al. 2008; Oddo et al. 2006).”
BackgroundDavis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373 · cited 1×
“However, the Tg model with the most extensive vascular amyloid in association with lower levels of parenchymal amyloid is the APPSwDI mouse which incorporates three APP mutations: Swedish, Dutch E693Q and Iowa D694N (Davis et al. 2004, 2006; Xu et al. 2007).”
BackgroundEvaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
Bayer, A. J., Bullock, R., Jones, R. W., Wilkinson, D., Paterson, K. R., Jenkins, L., Millais, S. B., & Donoghue, S. (2005) · Neurology · doi:10.1212/01.wnl.0000148604.77591.67 · Cited by 356 · cited 4×
“The initial trial was conducted in the UK and involved 80 patients with mild to moderate AD (Bayer et al. 2005).”
BackgroundResultInfluentialHoltzman, D. M., Bales, K. R., Wu, S., Bhat, P., Parsadanian, M., Fagan, A. M., Chang, L. K., Sun, Y., & Paul, S. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6179 · Cited by 349 · cited 1×
“In PDAPP mice expressing human apoE there was a marked delay in amyloid deposition compared to murine apoE expressing mice or apoE KO mice; however, the apoE4 expressing mice had increased levels of Ab deposits compared to apoE3 mice (Fryer et al. 2003; Holtzman et al. 1999, 2000).”
BackgroundCerebral amyloid angiopathy and cognitive function: The HAAS autopsy study
Pfeifer, L. A., White, L. R., Ross, G. W., Petrovitch, H., & Launer, L. J. (2002) · Neurology · doi:10.1212/wnl.58.11.1629 · Cited by 338 · cited 2×
“A number of reports have shown an increase in microhemorrhages in different AD mouse models following passive intraperito- neal immunization with different monoclonal antibodies with high affinity for Ab plaques and CAA (Pfeifer et al. 2002b; Racke et al. 2005; Wilcock et al. 2004).”
BackgroundInfluentialKlyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321
Racke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320
Monoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · cited 1×
“A small number of pre-clinical studies targeting Ab oligomers suggest that this methodology is potentially powerful and in the need of further development (Lam- bert et al. 2009, 2007; Lee et al. 2006; Mamikonyan et al. 2007; Moretto et al. 2007).”
BackgroundVidal, R., Révész, T., Rostagno, A., Kim, E., Holton, J. L., Bek, T., Bojsen-Møller, M., Braendgaard, H., Plant, G., Ghiso, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080076097 · Cited by 300 · cited 2×
“Mutations in BRI are associated with the cerebral amyloidoses of British and Danish dementias (Vidal et al. 1999; Vidal et al. 2000).”
BackgroundBiochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300 · cited 4×
“More than 20 protein kinases have been implicated in the phosphorylation of tau proteins, with glycogen synthase kinase-3b (GSK-3b) and cyclin-independent kinase (cdk5) thought to play the most important role in phosphorylation under pathological condition (Baumann et al. 1993; Buee et al. 2000; Hamdane et al. 2003; S…”
BackgroundInfluentialApolipoprotein E–dependent accumulation of Alzheimer disease–related lesions begins in middle age
Kok, E., Haikonen, S., Luoto, T., Huhtala, H., Goebeler, S., Haapasalo, H., & Karhunen, P. J. (2009) · Annals of Neurology · doi:10.1002/ana.21696 · Cited by 299
A decade of modeling Alzheimer's disease in transgenic mice
MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287 · cited 2×
“In these various Tg models the ratio of Ab 40–42, as well as the expression of ‘‘chaperone’’ proteins affects the type and distribution of amyloid deposits (McGowan et al. 2006; Wilhelmus et al. 2007; Wisniewski and Sadowski 2008).”
BackgroundBolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., & Jucker, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070403 · Cited by 281 · cited 1×
“Ab has also been shown to have such ‘‘infectious’’ properties in vivo, being able to induce an acceleration of both further Ab and tau related pathology (Bolmont et al. 2007; Eisele et al. 2009; Wisniewski et al. 1995).”
BackgroundInduction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation
Eisele, Y. S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L. H., Yan, Z.-X., Roth, K., Aguzzi, A., Staufenbiel, M., Walker, L. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903200106 · Cited by 279 · cited 4×
“…it has been shown that reducing the level of endogenous mouse tau can prevent behavioral deficits in APP Tg mice without affecting Ab levels (Roberson et al. 2007) and that exogenous Ab extracted from AD Tg mice can accelerate plaque deposi- tion in predisposed young Tg mice (Eisele et al. 2009).”
BackgroundInfluentialFryer, J. D., Simmons, K., Parsadanian, M., Bales, K. R., Paul, S. M., Sullivan, P. M., & Holtzman, D. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5170-04.2005 · Cited by 278 · cited 2×
“When these knock-in apoE3 and apoE4 mice were crossed to Tg2576 mice or more recently in PDAPP mice, the apoE4 mice had sig- nificantly more parenchymal amyloid deposition and more CAA then the apoE3 mice (Bales et al. 2009; Fryer et al. 2005).”
BackgroundFrackowiak, J., Wisniewski, H. M., Wegiel, J., Merz, G. S., Iqbal, K., & Wang, K. C. (1992) · Acta Neuropathologica · doi:10.1007/bf00227813 · Cited by 276
Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274
Aβ Species Removal After Aβ 42 Immunization
Nicoll, J. A. R., Barton, E., Boche, D., Neal, J. W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., et al. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240466.10758.ce · Cited by 265
Active and passive immunotherapy for neurodegenerative disorders
Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250 · cited 1×
“Currently, it appears that the greatest hope for an intervention that will significantly impact disease pro- gression in the near future comes from the vaccination approaches (Brody and Holtzman 2008; Wisniewski and Boutajangout 2009; Wisniewski and Konietzko 2008).”
BackgroundTakeuchi, A., Irizarry, M. C., Duff, K., Saido, T. C., Hsiao Ashe, K., Hasegawa, M., Mann, D. M. A., Hyman, B. T., & Iwatsubo, T. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64544-0 · Cited by 229
Alzheimer disease pathology as a host response
Castellani, R. J., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318177eaf4 · Cited by 171
Sadowski, M. J., Pankiewicz, J., Scholtzova, H., Mehta, P. D., Prelli, F., Quartermain, D., & Wisniewski, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604011103 · Cited by 167 · cited 1×
“…et al. 2009; Mahley and Huang 2009; Wilhelmus et al. 2007; Wisniewski and Sadowski 2008); however, one suggested role for apoE has been as a ‘‘pathological chaperone’’ that can induce a b-sheet conformation in Ab (Sadowski et al. 2006; Wisniewski et al. 1993, 1994; Wisniewski and Frangione 1992).”
BackgroundScholtzova, H., Kascsak, R. J., Bates, K. A., Boutajangout, A., Kerr, D. J., Meeker, H. C., Mehta, P. D., Spinner, D. S., & Wisniewski, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5715-08.2009 · Cited by 166 · cited 3×
“chymal amyloid without any associated increase in cerebral microhemorrhages (Scholtzova et al. 2009).”
BackgroundMethodSelf-citationAmyloid-β immunisation for Alzheimer's disease
Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155 · cited 3×
“Currently, it appears that the greatest hope for an intervention that will significantly impact disease pro- gression in the near future comes from the vaccination approaches (Brody and Holtzman 2008; Wisniewski and Boutajangout 2009; Wisniewski and Konietzko 2008).”
BackgroundColton, C. A., Vitek, M. P., Wink, D. A., Xu, Q., Cantillana, V., Previti, M. L., Van Nostrand, W. E., Weinberg, J. B., & Dawson, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601075103 · Cited by 128
Tampellini, D., Magrané, J., Takahashi, R. H., Li, F., Lin, M. T., Almeida, C. G., & Gouras, G. K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700373200 · Cited by 118 · cited 1×
“Another study has shown that antibodies against Ab can be internalized in AD neuronal culture models of Ab accumulation and clear intraneuronal Ab aggregates via the endosomal–lysosomal pathway (Tampellini et al. 2007).”
BackgroundDifferent distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases
Sergeant, N., David, J.-P., Lefranc, D., Vermersch, P., Wattez, A., & Delacourte, A. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00859-4 · Cited by 117 · cited 2×
“In some animal models expressing mutated tau there is an increase of 4R versus 3R tau (Sergeant et al. 1997).”
BackgroundLambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29
Cited by
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Chung, E., Ji, Y., Sun, Y., Kascsak, R. J., Kascsak, R. B., Mehta, P. D., Strittmatter, S. M., & Wisniewski, T. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-130 · Cited by 152
Self-citationInsights into Alzheimer disease pathogenesis from studies in transgenic animal models
Schaeffer, E. L., Figueiró, M., & Gattaz, W. F. (2011) · Clinics · doi:10.1590/s1807-59322011001300006 · Cited by 114
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Self-citationGoñi, F., Herline, K., Peyser, D., Wong, K., Ji, Y., Sun, Y., Mehta, P., & Wisniewski, T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-150 · Cited by 43
Metadata
- Authors
- Wisniewski, T., & Boutajangout, A.
- Venue
- Brain Structure and Function
- Published
- 2009-12-10
- Volume
- 214
- Issue
- 2-3
- Pages
- 201-218
- ISSN
- 1863-2653 (ISSN-L)
- 1863-2661
- OpenAlex
- W2001723966
- Cited by
- 38
- References
- 92
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.